Press release
Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics - Pipeline Analysis 2019 | Top Key Players- Daiichi Sankyo, Inc., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd, AstraZeneca, Amgen
Download the sample report @ https://www.pharmaproff.com/request-sample/1208
EGFR inhibitors therapies have shown improvement by inhibiting receptor signalling and enhancing the effects of radiation therapy and conventional chemotherapy with their anti-tumor activity. Cetuximab, Panitumumab, Erlotinib and Afatinib are some of the major marketed drugs as anti-EGFR therapies for the treatment of colorectal cancer, head and neck cancer and non-small cell lung cancer.
Get the detailed analysis @ https://www.pharmaproff.com/report/egfr-antagonists-therapeutics
Daiichi Sankyo Co., Ltd. is in the process of developing Nimotuzumab as a humanized monoclonal antibody which acts as an EGFR inhibitor for the treatment of gastric cancer. Some of the other companies having pipeline of EGFR inhibitors include Daiichi Sankyo Co., Ltd., Shionogi & Co. Ltd., AstraZeneca PLC, and Amgen Inc.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1208
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics - Pipeline Analysis 2019 | Top Key Players- Daiichi Sankyo, Inc., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd, AstraZeneca, Amgen here
News-ID: 1676955 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for EGFR
EGFR Inhibitors Market to Reach USD 16 Billion by 2034
Targeting Lung Cancer with Precision: EGFR Inhibitors Market to Reach USD 16 Billion by 2034
The global burden of non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, continues to rise, and so does the demand for more targeted, effective, and personalized treatments. Epidermal Growth Factor Receptor (EGFR) inhibitors have emerged as a game-changing class of targeted therapies that address EGFR gene mutations-common drivers in NSCLC patients, especially…
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Growth 2025: Trends, Consu …
The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.65 Bn in 2025 and is expected to reach USD 7.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
The Latest published market study on EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market report provides an overview of the current market dynamics as well…
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Clinical Trials 2024: EMA, PDMA, …
(New York, United States) As per DelveInsight's assessment, globally, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline constitutes 30+ key companies continuously working towards developing 30+ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the…
EGFR Non-Small Cell Lung Cancer Pipeline Report 2024
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,…
EGFR Mutation Test Market to Show Incredible Growth by 2027 | Novartis, Illumina
It shows how the COVID-19 health problem has affected a variety of companies. The COVID-19 epidemic and related lockdown countermeasures have wreaked havoc on several various segments of the economy; however, a few have seen growing demands. This EGFR Mutation Test market report's major objective is to forecast market growth from 2021 to 2027. A Market Report is the result of a data-driven strategy. It displays data in a visually…
EGFR Mutation Test Market Estimated to Flourish by 2016 – 2024
Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are…
